Clinical trial
An Open-label, Balanced, Randomized, Two-period, Crossover, Single Dose Study to Compare the Bioavailability of PanCytoVir™ Oral Suspension (100mg/ml), in Healthy, Adult, Human Subjects Under Fed and Fasting Conditions
NCT06025318 is registered in ClinicalTrials.gov with TrippBio, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Balanced, Randomized, Two-period, Crossover, Single Dose Study to Compare the Bioavailability of PanCytoVir™ Oral Suspension (100mg/ml), in Healthy, Adult, Human Subjects Under Fed and Fasting Conditions
- Lead sponsor
- TrippBio, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- September 1, 2024
- Completion date
- October 15, 2024
- Enrollment
- 14 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
relative bioavailability